Muhlenkamp & Co. Inc. continued to hold its position in MacroGenics, Inc. (NASDAQ:MGNX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,167 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Muhlenkamp & Co. Inc.’s holdings in MacroGenics were worth $231,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in MGNX. Russell Investments Group Ltd. bought a new stake in MacroGenics in the second quarter valued at approximately $133,000. Legal & General Group Plc lifted its position in MacroGenics by 4.3% in the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 328 shares during the last quarter. SG Americas Securities LLC lifted its position in MacroGenics by 92.2% in the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 5,187 shares during the last quarter. American International Group Inc. lifted its position in MacroGenics by 7.1% in the first quarter. American International Group Inc. now owns 19,632 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Stifel Financial Corp lifted its position in MacroGenics by 7.8% in the first quarter. Stifel Financial Corp now owns 20,155 shares of the biopharmaceutical company’s stock valued at $370,000 after purchasing an additional 1,450 shares during the last quarter. Institutional investors own 84.47% of the company’s stock.

Several analysts have weighed in on the company. Stifel Nicolaus reiterated a “buy” rating and issued a $34.00 price objective on shares of MacroGenics in a research report on Tuesday, September 12th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $26.00 price objective on shares of MacroGenics in a research report on Friday, September 1st. ValuEngine downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. BidaskClub upgraded MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Zacks Investment Research downgraded MacroGenics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $30.30.

MacroGenics, Inc. (NASDAQ:MGNX) traded up 0.40% during trading on Tuesday, hitting $17.67. The stock had a trading volume of 61,304 shares. The stock has a 50 day moving average price of $17.04 and a 200-day moving average price of $18.33. MacroGenics, Inc. has a 12 month low of $14.36 and a 12 month high of $32.68. The stock’s market cap is $650.22 million.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.09). MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $15.82 million. During the same quarter last year, the company earned $1.12 EPS. The business’s revenue for the quarter was down 97.9% compared to the same quarter last year. On average, equities analysts predict that MacroGenics, Inc. will post ($4.42) EPS for the current year.

TRADEMARK VIOLATION WARNING: “MacroGenics, Inc. (MGNX) Stake Maintained by Muhlenkamp & Co. Inc.” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/19/macrogenics-inc-mgnx-stake-maintained-by-muhlenkamp-co-inc.html.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.